Detailed narrative
Ulixacaltamide Regulatory and Commercial Progress
The FDA has completed mid-cycle communications for ulixacaltamide, indicating no efficacy-related significant issues and no plans for an advisory committee meeting, which is a positive signal for its potential approval by January next year. Praxis has established commercial leadership, initiated field force hiring and training, and built a distribution network, with inventory being prepared for launch. The company is also exploring life cycle opportunities for T-type calcium channel inhibitors, including a collaboration with Remagine Labs to expand ulixacaltamide's reach.
Relutrigine Regulatory and Commercial Readiness
Relutrigine's PDUFA target has been extended to December 27 this year due to a major amendment submission, but the FDA has confirmed no advisory committee meeting is planned. The addressable population for SCN2A and SCN8A-DEE is approximately 10,000 patients in the US. Commercial and medical teams are fully hired, the supply chain is established, and a comprehensive patient support program is in place, positioning the company for a structured launch. The EMERALD study for broader DEEs has exceeded its enrollment target with about 200 patients, laying the groundwork for a supplemental NDA in 2027.
Vormatrigine Program Revamp
The POWER1 study for vormatrigine in focal onset seizures did not meet its primary endpoint, but a key secondary endpoint (50% reduction in seizure frequency) was met, suggesting efficacy for a subset of patients. Management attributes the primary endpoint miss to dose and study design elements, which are considered fixable. Plans are being finalized to amend and revamp both POWER2 and POWER3 studies, with an aim to have them operational by Q4 this year, incorporating learnings from POWER1.
Elsunersen Breakthrough Therapy Designation
Elsunersen received Breakthrough Therapy Designation (BTD) from the FDA for seizures associated with SCN2A DEE caused by gain-of-function variants, based on results from the EMBRAVE Part A study. This marks the third BTD for Praxis since July last year, highlighting the company's pipeline productivity. The EMBRAVE3 study for elsunersen is enrolling well, with top-line results anticipated next year.
Financial Position and Cash Runway
Praxis reported operating expenses of $96.9 million in Q2 FY26, with R&D at $69.4 million and G&A at $27.5 million. Operating cash burn was $78 million for the quarter. The company ended Q2 FY26 with $1.4 billion in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028. G&A expenses are projected to increase in H2 FY26 to support upcoming product launches.
Commercial Strategy and Payer Landscape
For ulixacaltamide, Praxis anticipates an addressable population of around 2 million patients at launch, with approximately three-quarters being Medicare/Medicare Advantage patients. The company's pricing assumptions are in the $50,000 to $100,000 per year range. Payer discussions indicate readiness for day-one coverage, with a significant portion of the market unable to medically take propranolol. The commercial field force for ulixacaltamide is expected to be around 300, targeting 13,000 to 15,000 neurologists.